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Optimal T cell activation requires the delivery 
of costimulatory signals concomitant with T cell 
receptor engagement. CD28 is perhaps the 
most important and best-studied costimulatory 
receptor and is unique in its potency to aug-
ment IL-2 production. Ligation of CD28 
  increases cell proliferation and enhances cell 
survival as well as regulating production of mul-
tiple T cell–derived cytokines (1). Consistent 
with this, T cells from mice defi  cient in CD28 
have impaired proliferative responses, make lit-
tle IL-2, and have increased susceptibility to 
apoptosis (2–5). Although the importance of 
CD28 in T cell function is well established, 
many questions remain as to the mechanism by 
which CD28 mediates its biological eff  ects.
CD28 is most critical in the activation of 
resting, naive T cells. Furthermore, the primary 
outcomes of CD28 signaling are changes in cell 
proliferation and survival. Previous work ex-
amining the structural motifs responsible for 
CD28 function have relied on either trans-
formed cell lines, retroviral transduction of pri-
mary T cells, or reconstitution of CD28-defi  cient 
mice with transgenic constructs under the con-
trol of heterologous promoters. Although these 
have led to important insights, the results have 
often been confl   icting and each has experi-
mental limitations that make extrapolation to 
primary, naive T cells problematic.
CD28 possesses no intrinsic enzymatic ac-
tivity; however, discrete regions within the cy-
toplasmic tail interact with intracellular adaptor 
proteins and enzymes to initiate signaling. 
  Mutagenesis studies have identifi  ed two regions 
of the tail as being of particular importance. 
A tyrosine-based motif in the membrane prox-
imal region of the cytoplasmic domain binds 
and activates PI-3 kinase, as well as interacting 
with the adaptor proteins Grb-2 and GADS 
(6–11). Less well characterized is a proline-based 
motif in the distal portion of the cytoplasmic 
domain. This region can interact with SH3 
  domain containing proteins including the Src 
family kinases Lck and Fyn to initiate signaling 
(7, 12). Recent studies have been confl  icting as 
to the importance of this motif in CD28-de-
pendent responses, with some suggesting that it 
is critical for enhancing proliferation and IL-2 
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secretion, whereas others indicate that it is dispensable for 
these functions but required for IL-4 production (13–16). 
Moreover, the requirement for this motif in the generation 
of a complex, in vivo immune response is unknown.
Given the importance of CD28 in the activation of naive 
T cells and that CD28 expression is itself regulated by cell ac-
tivation, we generated a targeted knockin mouse expressing a 
mutation of the distal proline motif to determine its function. 
The CD28 P187,190A knockin (CD28-AYAA KI) mice 
thus express only the mutant form of CD28. In contrast with 
other experimental approaches, the genetic elements that 
regulate transcription are preserved and thus the mutant pro-
tein is expressed and regulated in a manner identical to the 
endogenous gene product. This strategy permits both in vitro 
and in vivo analysis of the functional consequences of the 
mutation with less concern that the results are the result of 
aberrant patterns of expression. In these studies, we fi  nd that 
the proline motif is critical for normal CD28-dependent reg-
ulation of IL-2 production and is absolutely required for 
  antibody production and germinal center formation in vivo. 
Furthermore, we demonstrate that gene dosage is important 
in determining the phenotype of this mutation.
RESULTS
Generation of CD28 P187,190A knockin mice
To generate mice expressing mutant CD28 under endoge-
nous regulatory control, we constructed a gene targeting vec-
tor containing exon IV of CD28 and fl  anking  intronic 
sequences (Fig. 1 A). Specifi  c mutations were introduced to 
substitute alanine for proline at residues 187 and 190, thus 
disrupting the motif responsible for interaction with SH3 
  domain–containing proteins (Fig. 1 B). This construct was 
transfected into murine embryonic stem cells and positive 
clones injected in C57BL/6 blastocysts. Germline transmis-
sion was verifi  ed by restriction mapping, Southern blotting,   
and sequencing (Fig. 1 C). To remove the Neomycin cas-
sette, pups were crossed with mice carrying Cre-recombinase 
as a transgene under the control of the E2A promoter 
Figure 1.  Generation of CD28-AYAA knockin mouse. (A) A 14-kB 
genomic fragment containing exon IV and fl  anking intronic sequences 
was cloned from a murine 126/Sv library. The loxP-fl  anked neomycin re-
sistance cassette was inserted into the 5′ intronic sequence. Point muta-
tions, indicated by the asterisk, were introduced into exon IV at positions 
187 and 190. The resultant recombinant allele contained two new EcoRI 
sites as well as the mutation. The shaded portion of exon IV represents 
the coding region. (B) Amino acid sequence of the cytoplasmic domain of 
CD28 coded for by the wild-type and mutant allele. (C) Southern blotting 
of wild-type and heterozygous mutant mice using a 3′ external probe on 
EcoRI-digested DNA and a 5′ external probe on BglII-digested DNA. Suc-
cessful Cre-mediated excision of the Neo cassette was verifi  ed by loss of 
the 6.0-kB band on the BglII-digested DNA as well as using PCR strategy 
with primers p1 and p2 as indicated in A. The post-Cre recombinant allele 
is slightly larger than the endogenous allele as the result of remaining 
DNA introduced by the targeting vector.JEM VOL. 203, September 4, 2006  2123 
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(initially generated by H. Westphal, National Institutes of 
Health (NIH) and provided to us in the C57BL/6 back-
ground by M. Bessler, Washington University School of 
Medicine). This strategy results in high expression of Cre-
  recombinase in the ovum, and results in effi   cient excision of 
the Neo cassette in the resultant zygote (17, 18). Loss of the 
Neo cassette was verifi   ed by Southern blotting of BglII-
  digested DNA using a 5′ external probe, as well as by PCR 
analysis using primers that flank the remaining introduced 
DNA (Fig. 1 C). Mice carrying the recombinant allele were 
then bred to CD28-defi  cient mice to generate mice hetero-
zygous for the mutant CD28-AYAA KI allele (CD28 
AYAA/−). These mice have a single copy of the mutant gene 
and express only the mutant CD28 protein. Additional breed-
ings were established to generate off  spring that are either 
CD28+/+, CD28+/−, CD28−/−, or homozygous mutant (CD28 
AYAA/AYAA) in a similar mixed genetic background.
To determine whether T cells carrying the mutant CD28-
AYAA allele expressed the protein at a level comparable to 
endogenous CD28, splenocytes and thymocytes were iso-
lated from CD28 AYAA/−, CD28 AYAA/AYAA, CD28+/−, 
CD28+/+, and CD28−/− mice and stained with FITC-con-
jugated anti-CD4 and PE conjugated anti-CD28 and ana-
lyzed by fl  ow cytometry (Fig. 2 A). The expression of mutant 
CD28 was comparable to the wild-type protein in both the 
heterozygous and homozygous states. After activation with 
anti-CD3 alone or anti-CD3 and anti-CD28, both wild-type 
and mutant alleles had similar expression patterns (Fig. S1, 
available at http://www.jem.org/cgi/content/full/jem.
20052230/DC1). Thus, surface expression of the CD28-
AYAA KI allele appears to be regulated during T cell activa-
tion in a manner similar to that of the endogenous alleles. To 
confi  rm that the expressed allele did in fact encode the de-
sired mutation, RNA was isolated from wild-type or mutant 
thymocytes and the message for CD28 was amplifi  ed by RT-
PCR. The mutation at position 187 introduces a new HaeIII 
site, which is apparent by the unique banding pattern seen in 
the sample prepared from the mutant and further confi  rmed 
by sequence analysis (Fig. 2 B and not depicted).
Impaired IL-2 production in T cells from CD28-AYAA 
KI mice
CD28 is unique among costimulatory receptors in the po-
tency with which it regulates IL-2. We therefore directly as-
sayed the amount of IL-2 present in the culture supernatants 
of stimulated T cells from wild-type and CD28-AYAA 
knockin mice (Fig. 3 and Table I). There was a marked re-
duction in IL-2 production from T cells isolated from CD28-
AYAA mice. Consistent with previous reports, CD28+/− 
mice had an  50% reduction in IL-2 (2). In contrast, there 
was no detectable IL-2 in cultures from CD28 AYAA/− 
mice. Furthermore, the maximal IL-2 produced by CD28 
AYAA/AYAA–expressing T cells was one third of that of 
CD28+/+ cells. IL-2 secretion was also absent in both the 
CD28 AYAA/− and CD28 AYAA/AYAA mice after stimu-
lation with PMA and anti-CD28 (unpublished data). How-
ever, all genotypes produced signifi  cant amounts of IL-2 after 
stimulation with PMA and ionomycin (Fig. 3). Although 
there was a reduction in IL-2 secretion observed in both the 
CD28-defi   cient and CD28-AYAA mutant in response to 
Figure 2.  Expression of CD28 on wild-type and mutant mice. 
(A) Thymocytes and splenocytes were isolated from CD28+/+, CD28+/−, 
CD28 AYAA/− CD28 AYAA/AYAA, and CD28−/− mice and stained for both 
CD4 and CD28. Shown are histograms of CD28 expression of each geno-
type after gating on CD4+ T cells. The expression of the mutant protein is 
equivalent to the endogenous protein. (B) Total RNA was isolated from 
thymocytes of CD28+/+ or CD28 AYAA/AYAA mice. RT-PCR was performed 
using primers that span exons I–IV. The PCR product was digested with 
HaeIII. The distinct banding pattern confi  rms that the transcribed RNA 
encodes for the desired mutation.2124   REQUIREMENT FOR THE CD28 C-TERMINAL PROLINE MOTIF | Friend et al.
PMA + ionomycin as compared with controls, this was not 
consistently observed. Importantly, these data demonstrate 
that there is not a generalized impairment in IL-2 production 
that would account for the profound defi  ciency observed af-
ter stimulation with anti-CD3 and anti-CD28. Thus, normal 
regulation of IL-2 production by CD28 requires signals initi-
ated by the PYAP motif.
To determine if the eff  ect of the mutation was specifi  c for 
IL-2 production or if it was representative of a more global 
defect in cytokine expression, we assayed a larger panel of T 
cell–derived cytokines (Table I). Mice expressing the mutant 
allele had a substantial reduction in the amount detected of 
several cytokines. These data suggest a more general require-
ment for the PYAP motif in CD28-dependent regulation of 
cytokine production.
Impaired proliferation in T cells from CD28-AYAA mice
A fundamental property of CD28 costimulation is the aug-
mentation of T cell proliferation, in particular to submito-
genic levels of TCR engagement (19). To determine the 
eff   ect of the P187,190A mutation on CD28-dependent 
  proliferation, splenocytes from CD28+/+, CD28 AYAA/−, 
CD28+/− and CD28−/− mice were stimulated with increas-
ing concentrations of anti-CD3 (0.01–10 μg/ml) alone or in 
combination with anti-CD28 mAb (1 μg/ml, clone PV-1) 
or CTLA4Ig (10 μg/ml) and proliferation was determined by 
[3H] thymidine incorporation (Fig. 4 A). T cells from CD28 
AYAA/− mice had a marked defect in proliferative response 
to anti-CD3 alone and to the combination of anti-CD3 + 
anti-CD28. This was not the result of a reduction in expres-
sion as the CD28+/− and CD28-AYAA/− cells expressed 
Figure 3.  Diminished IL-2 production in CD28 AYAA mice. Splenocytes 
were isolated from each of the indicated genotypes. Cultures were stimu-
lated with graded doses of anti-CD3 alone or in the presence of 1.0 μg/ml 
anti-CD28 and IL-2 assayed in the culture supernatants after 48 h by 
ELISA. Representative data are shown from fi  ve independent experiments.
Table I. Multiple cytokines are dependent on the proline motif of CD28
CD28+/+   CD28 AYAA/AYAA   CD28−/−
 CD3 CD3/CD28 CD3 CD3/CD28 CD3 CD3/CD28
IL-2 22.63 503.92 19.30 30.00 3.69 5.03
IL-4 1.46 22.15 2.78 11.47 0.45 0.60
Il-5 ND 9.37 0.41 0.69 ND ND
IL-10 1.52 33.01 5.78 17.93 1.26 1.85
IL-12 1.19 5.79 0.47 2.09 1.39 0.15
GMCSF 5.28 27.20 4.20 12.59 ND 1.97
IFN-𝗄 3.16 1,086.72 17.12 245.16 0.67 0.71
TNF-𝗂 0.66 8.95  0.86 4.66   1.83 1.78
Splenocytes from the indicated genotypes were cultured with media alone, or activated with 1.0 μg/ml anti-CD3 alone or in combination with 1.0 μg/ml anti-CD28. Culture 
supernatants were harvested at 48 h and assayed for cytokine levels using the Th1/Th2 Bioplex multicytokine kit (BioRad Laboratories). All data are in pg/ml and the mean of 
triplicate samples presented.JEM VOL. 203, September 4, 2006  2125 
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comparable levels of CD28 (Fig. 2). In contrast with the re-
sults seen with cells from the CD28-AYAA/− heterozygous 
mice, proliferation of T cells from homozygous CD28-AYAA/
AYAA mutant mice was near wild-type levels (Fig. 4 B). 
This reveals an important gene dosage eff  ect, with a greater 
defect apparent at the lower expression levels seen in the 
  heterozygous state.
We reasoned that the profound proliferative defect ob-
served in cells from the heterozygous mutant might refl  ect 
limiting IL-2 availability. Although addition of exogenous 
IL-2 increased the proliferation of cells from both CD28−/− 
and CD28 AYAA/− mice, it did not fully restore it to the 
level observed in the CD28+/− cultures (Fig. 4 C). This sug-
gests that the proliferative defect in both the CD28-defi  cient 
and CD28-AYAA mutant is partially, but not solely, the re-
sult of limiting IL-2.
To determine the response to physiologic engagement of 
the TCR and CD28 with natural ligand, we stimulated cells 
of each genotype with alloantigen in a mixed lymphocyte 
culture (Fig. 4 E). Both homozygous and heterozygous 
  mutant cells failed to proliferate, whereas cells expressing 
wild-type CD28 mounted a robust proliferative response. 
In addition, neither homozygous nor heterozygous CD28-
AYAA mutant mice proliferated after activation with PMA 
and anti-CD28 (Fig. 4 D). Importantly, all genotypes prolif-
erated in response to PMA and ionomycin and had similar 
expression of CD69 after activation (Fig. 4 D and Fig. S2, 
available at http://www.jem.org/cgi/content/full/jem.
20052230/DC1). Thus, there is a relative requirement for 
the C-terminal proline residues after activation by anti-CD3 
and anti-CD28 that is partially overcome by increased ex-
pression levels, whereas there is an absolute requirement for 
Figure 4.  Impaired proliferation in cells from CD28 AYAA mice. 
(A and B) Splenocytes were isolated from each of the indicated genotypes 
and stimulated with graded doses of anti-CD3 alone, with 10 μg/ml 
  CTLA4Ig or with 1.0 μg/ml anti-CD28. (C) Splenocytes were stimulated 
with 0.01 μg/ml anti-CD3 alone, with 1.0 μg/ml anti-CD3 and anti-CD28, 
or with 100 U/ml anti-CD3, anti-CD28, and exogenous IL-2. Proliferation 
was measured after 48 h. (D) Replicate cultures were stimulated with 
either PMA alone, PMA + ionomycin, or PMA + anti-CD28. Proliferation 
was measured after an overnight pulse with tritiated thymidine initiated 
at 48 h. (E) Splenocytes of the indicated genotypes (R) were cocultured 
with irradiated allogeneic splenocytes (S) for 96 h and proliferation was 
determined by tritiated thymidine incorporation. Representative data are 
shown from a minimum of three independent experiments.2126   REQUIREMENT FOR THE CD28 C-TERMINAL PROLINE MOTIF | Friend et al.
this motif for proliferation induced by alloantigen or by PMA 
and anti-CD28.
Proliferation was also determined by CFSE dye dilution. 
Splenocytes were loaded with CFSE and stimulated with 
anti-CD3 alone or in combination with anti-CD28. At 48, 
72, and 96 h after stimulation, aliquots of cells were stained 
with anti-CD4–PE and analyzed by two-color fl  ow cytometry. 
Presented in Fig. 5 is the percentage of CD4+ T cells that 
have undergone at least one cell division at 72 h. Representa-
tive histograms obtained from cultures stimulated with 0.01 
μg/ml anti-CD3 alone (Fig. 5, left) or anti-CD3 + anti-
CD28 (Fig. 5, right) are also shown. Markedly fewer cells 
expressing the mutant CD28 undergo cell division than cells 
expressing the wild-type allele, thus independently confi  rm-
ing the results obtained by thymidine incorporation. A simi-
lar pattern of results was observed at 48- and 96-h time points 
(unpublished data).
We consistently found that the homozygous CD28 
AYAA mutant cells manifest a 1-log shift in the dose re-
sponse to anti-CD3 as compared with control cultures (Fig. 
4 B). In these experiments, endogenous CD80 and CD86 
present on the APCs in the culture provided costimulation as 
indicated by the abrogation of proliferation after inclusion of 
CTLA4Ig. In addition, activation by alloantigen, which uti-
lizes endogenous B7:CD28 interactions, was markedly im-
paired. This led us to hypothesize that diff  erences in the level 
of receptor engagement between endogenous B7 and anti-
CD28 mAb might be important in determining the conse-
quence of the mutation. To investigate this, we stimulated 
splenocytes with anti-CD3 in the presence of CTLA4Ig to 
block endogenous costimulation and titrated in increasing 
amounts of anti-CD28 mAb (Fig. 6). In both the heterozy-
gous and homozygous mutants, proliferation was markedly 
impaired at lower doses of anti-CD28. The eff  ect was even 
more profound at submitogenic doses of anti-CD3 (unpub-
lished data). Thus, at limiting levels of antigen receptor and 
CD28 engagement, signaling through the proline motif is 
critical for T cell proliferation.
Up-regulation of BclXL expression
In addition to regulating cell proliferation and cytokine 
  production, CD28 costimulation enhances cell survival. 
Figure 5.  Decreased cell division in T cells from CD28 AYAA mice. 
Splenocytes from the indicated genotypes were loaded with CFSE and 
stimulated with anti-CD3 alone or in combination with anti-CD28. 72 h 
after stimulation, the cells were stained with PE-conjugated anti-CD4 and 
analyzed by two-color fl  ow cytometry. Shown is the percentage of cells 
having undergone at least one cell division. Representative CFSE histo-
grams from cultures stimulated with 0.01 μg/ml anti-CD3. Shown is rep-
resentative data from three independent experiments.JEM VOL. 203, September 4, 2006  2127 
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One mechanism by which this occurs is up-regulation of the 
antiapoptotic protein BclXL (20). Previous work has deter-
mined this to be downstream of PI-3 kinase activation and 
requires the tyrosine-based motif in the proximal portion of 
the cytoplasmic domain of CD28 (21–24). We had previ-
ously demonstrated that the expression pattern of Bcl-XL was 
preserved in CD28-defi  cient T cells retrovirally transduced 
with the CD28-AYAA mutation (14). However, in that sys-
tem, the T cells had been previously activated to facilitate 
gene transduction. We therefore tested whether CD28-de-
pendent regulation of Bcl-XL expression was intact in naive 
T cells isolated from the CD28-AYAA KI mice. As expected, 
CD28-defi  cient T cells failed to increase BCL-XL expression 
in response to anti-CD28 costimulation. Both CD28+/− and 
CD28 AYAA/− T cells up-regulated BCL-XL, although the 
increase in the AYAA mutant cells was less than that of the 
CD28+/− cells (Fig. 7). Thus, consistent with our previous 
fi  ndings and work demonstrating a strict requirement for the 
upstream tyrosine-based motif in regulation of Bcl-XL, up-
regulation was not absolutely dependent on the proline-based 
motif (14, 23). However, there does appear to be some 
  contribution to Bcl-XL expression mediated by signaling ini-
tiated by the proline motif. Nonetheless, these data do dem-
onstrate that mutation of the C-terminal proline motif does 
not globally impair CD28 function.
CD28-AYAA KI mice manifest impaired humoral 
immunity in vivo
The aforementioned experiments demonstrate the impor-
tance of the PYAP motif in the regulation of T cell prolifera-
tion and IL-2 production in vitro. However, these fi  ndings 
may not accurately recapitulate events in vivo. The CD28-
AYAA knockin mice provide a powerful tool to deter-
mine the role of signaling pathways initiated by the PYAP 
motif during an in vivo T cell–dependent immune response.
Experimental allergic airway infl  ammation is a model of a 
Th2 immune response characterized by an eosinophilic in-
fl  ammatory cell infi  ltrate in the lung (25). Mice treated with 
soluble inhibitors of B7 or CD28-defi  cient mice develop no 
infl  ammatory or antibody response (26–28). To determine 
if the PYAP motif of CD28 was required, CD28-AYAA KI 
or control mice were sensitized and challenged with OVA. 
Figure 6.  Diminished sensitivity to anti-CD28 in T cells from CD28 
AYAA mutant mice. (A) Splenocytes from CD28+/+, CD28+/−, or CD28 
AYAA/− mice were isolated and stimulated with 0.1 μg/ml of anti-CD3 
alone, with the addition of 10 μg/ml CTLA4Ig to block endogenous CD80 
or CD86, or with graded doses of anti-CD28 (0.03, 0.3, or 1.0 μg/ml). 
Proliferation was measured by tritiated thymidine incorporation after 
48 h of culture. (B) Splenocytes from CD28+/+, CD28−/−, or homozygous 
mutant mice (CD28 AYAA/AYAA) were isolated and stimulated described in A. 
Representative data are shown from three independent experiments.
Figure 7.  CD28-dependent up-regulation of Bcl-XL. Splenocytes 
from the indicated genotypes were activated with 1.0 μg/ml anti-CD3 
alone or with 1.0 μg/ml anti-CD28 for 48 h. The cells were stained with 
FITC-conjugated anti-CD4, fi  xed, permeabilized, and stained with anti-
BclXL antibody followed by a PE-conjugated secondary. Shown are repre-
sentative histograms of Bcl-XL expression after gating on CD4+ T cells. 
Representative data are shown from three independent experiments.2128   REQUIREMENT FOR THE CD28 C-TERMINAL PROLINE MOTIF | Friend et al.
  Despite the aforementioned profound in vitro defects, mice 
heterozygous for the mutant allele developed similar airway 
infl  ammation as wild-type control mice, as assessed by bron-
choalveolar lavage and histology (Fig. 8).
In contrast with the normal tissue infl  ammation observed 
in the mutant mice, there was a marked decrease in OVA-
specifi  c antibody relative to wild-type controls (Fig. 9, A and B). 
This was accompanied by a failure of the CD28-AYAA KI 
mice to develop germinal centers (GCs) in the spleen as 
  determined by staining with PNA and anti-IgD (Fig. 9, C–E). 
Mice expressing mutant CD28 had a 5-fold reduction in GCs 
per 10× fi  eld or a >20-fold reduction in total GCs per sec-
tion as compared with mice expressing wild-type CD28. 
This was evident in both heterozygous and homozygous 
CD28-AYAA KI mice. Thus, there is an absolute require-
ment for the PYAP motif in the development of OVA-
  specifi  c antibodies and GC formation in vivo. Furthermore, 
this mutation dissociates specifi  c CD28-dependent elements 
of the immune response, as the CD28-AYAA were able to 
mount a normal infl   ammatory response in the tissue, yet 
failed to produce a humoral response, whereas wild-type mice 
have both elements and CD28-defi  cient mice have neither.
D  I  S  C  U  S  S  I  O  N 
CD28 was fi  rst described in studies reporting that ligation 
of a 44-kD protein, Tp44, on the surface of human T cells 
augmented proliferation induced by PHA or alloantigen and 
IL-2 production (19, 29). Numerous papers have been sub-
sequently published characterizing the profound eff  ect  of 
CD28 on T cell function in particular and its importance 
in regulating IL-2 expression and proliferation. Later work 
identifi  ed CD28 as a determinant of cell survival and metab-
olism through regulation of the antiapoptotic protein Bcl-XL 
and promotion of glucose uptake and utilization, respectively 
(20, 30, 31). Thus, CD28 directly regulates several pro-
cesses critical for the growth, survival, and eff  ector function 
of T cells.
Although it is clear that CD28 activates multiple signaling 
pathways, the contribution of each to the downstream eff  ec-
tor functions of CD28 remains controversial. Much of the 
confl  icting data may arise from the nature and diff  erences in 
the experimental systems that have been used. Many of these 
studies have used transformed cell lines that have intrinsic ab-
normalities in proliferation and survival, making extrapola-
tion to primary cells diffi   cult. To circumvent this problem, 
several groups have used retroviral gene transfer into primary 
cells; however, this requires activation of the T cell to facili-
tate infection. Therefore, the cells are no longer naive (13, 14). 
Given that CD28 is most important in the initial activation 
of resting naive T cells, this approach is also problematic. In 
addition, expression levels of the retrovirally transduced gene 
are variable and not regulated in a manner analogous to the 
endogenous gene product. Although reconstitution of 
the CD28-defi  cient mice with specifi  c transgenes avoids the 
problem of cell activation and therefore allows for the study 
of naive cells, the use of heterologous promoters alters the 
regulation of expression. Thus, none of these experimental 
approaches faithfully recapitulate endogenous CD28. In con-
trast, the knockin mouse we have described allows the study 
of CD28 in naive T cells under conditions in which expres-
sion is correctly regulated by endogenous genetic elements.
The C-terminal proline motif can bind SH3 domain con-
taining proteins including the Src family kinases Lck and Fyn, 
the Tec kinase Itk, and the adaptor protein Grb2 (7, 11, 12, 
15, 32–34). Knockin mice expressing a single copy of CD28 
containing a mutation of this region had a profound defect in 
IL-2 production and proliferation after activation with anti-
CD3 and anti-CD28, demonstrating that this motif is critical 
in the regulation of these functions. Higher expression levels 
present in homozygous mutant mice restored proliferation to 
near wild-type levels, but IL-2 secretion remained severely 
impaired. In contrast, activation by alloantigen in which both 
the TCR and CD28 are engaged by endogenous ligand failed 
to induce proliferation in cells from either homozygous or 
heterozygous mutant mice. Thus, under activation condi-
tions that more closely model physiologic engagement of 
CD28, this motif is critical regardless of expression level. 
Similarly, there was an absolute defect in proliferation and 
IL-2 secretion after activation by PMA + anti-CD28 in 
both heterozygous and homozygous mutant mice, confi  rm-
ing a requirement for this motif in some CD28-dependent 
signaling pathways.
Figure 8.  Allergic airway infl  ammation is intact in CD28-AYAA 
mice. Mice of each genotype were systemically sensitized to OVA and 
given an inhaled challenge. 72 h after challenge, the BAL and lung tissue 
were collected for analysis. There was no difference in cell recovery or 
differential analysis of the BAL fl  uid obtained from the wild-type CD28 
AYAA mice. Similarly, histologic examination revealed infl  ammation in 
both wild-type and CD28 AYAA mutant mice, but not CD28−/− mice. 
  Representative data are shown from three independent experiments.JEM VOL. 203, September 4, 2006  2129 
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The importance of this region is consistent with early 
studies in cell lines in which deletion of this region abrogated 
CD28-dependent IL-2 production (35–37), and are support-
ive of some studies using retroviral gene transfer (14, 15). 
However, recent publications examining this have been con-
fl   icting. Andres et al. transduced bone marrow cells from 
CD28-defi  cient mice with a series of mutant CD28 con-
structs and demonstrated that no single motif was absolutely 
required for proliferation and IL-2 production; however, IL-4 
production did require the C-terminal proline residues 
(13). Tai et al. addressed this question by reconstituting 
CD28-defi   cient mice with mutant CD28 transgenic con-
structs controlled by the CD2 promoter (16). These studies 
demonstrated that the proline motif is required for CD28-
dependent IL-2 production after stimulation with PMA and 
anti-CD28, as well as for the generation of regulatory T cells 
in vivo independent of the eff  ect on IL-2. Our data are in 
agreement with a requirement for the C-terminal proline 
residues for the normal regulation of IL-2 production and 
proliferation by CD28. Importantly, our data provide an ex-
planation for the reported diff  erences in these datasets. Our 
data clearly demonstrate that higher expression levels, which 
might be achieved in some retrovirally transduced cells, un-
der some experimental conditions may mask the requirement 
for this motif. Furthermore, we demonstrate that there is an 
absolute requirement for an intact PYAP motif when the 
cells are activated by PMA and anti-CD28 or by alloantigen, 
whereas activation by anti-CD3 and anti-CD28 is less depen-
dent on the distal proline residues. Thus, diff  erences in both 
expression levels and activation conditions account for the 
reported discrepancies in the requirement for this region in 
the regulation of proliferation and IL-2.
Given the defects in proliferation and cytokine secretion, 
we examined signaling pathways activated after T cell activa-
tion. We saw no diff  erence in either total protein tyrosine 
phosphorylation or ERK phosphorylation after stimulation 
with anti-CD3 and anti-CD28 antibody in primary T cells 
from either wild-type or mutant mice (Fig. S3, available 
at http://www.jem.org/cgi/content/full/jem.20052230/DC1). 
Although other reports have demonstrated CD28-dependent 
eff  ects in these assays, we failed to reproduce these observa-
tions (34, 38). It is possible that diff  erences in experimental 
systems may account for this discrepancy.
In vivo, CD28 is engaged by CD80 or CD86 on the sur-
face of an APC. Recent studies suggest that the B7:CD28 in-
teraction may be monovalent and therefore may not induce 
Figure 9.  Impaired IgG and germinal center formation in vivo. 
(A and B) Serum was collected from mice (n = 3–5 mice/group) that had 
been systemically immunized with OVA/alum as described for Fig. 8. OVA-
specifi  c IgG1 was assayed by ELISA. p-values were calculated by two-
tailed Student’s t test. (C and D) Whole spleens were collected from 
OVA-immunized mice and frozen sections were stained with IgD and PNA 
to detect germinal centers. Only mice expressing wild-type CD28 had 
detectable germinal center formation after immunization. (E) Representa-
tive sections of spleen from each genotype stained with anti-IgD and 
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a high degree of receptor cross-linking (39, 40). In contrast, 
saturating doses of anti-CD28 mAb are likely to lead to ex-
tensive cross-linking and may activate signaling pathways that 
would not be activated under more physiologic conditions. 
Consistent with this hypothesis, we found that the prolifera-
tive defect in the CD28-AYAA mutant cells was more pro-
found under conditions of endogenous costimulation or 
limiting amounts of mAb.
A large body of work has focused on the proximal motif 
centered around the tyrosine at position 170 (Y170), which 
is critical for PI-3 kinase activation as well as binding the 
adaptor proteins Grb2 and GADS through their SH2 domain 
(8, 9, 11, 41). Controversy exists as to the precise role of 
CD28-dependent activation of PI-3 kinase in the regulation 
of proliferation and IL-2 secretion. Recent studies have pro-
vided some resolution, with several confi  rming the impor-
tance of this pathway in induction of Bcl-XL (14, 23). More 
recently, it has been demonstrated that mutation of this motif 
abrogated CD28-dependent regulation of IL-2 transcription, 
yet leaves the posttranscriptional regulation of IL-2 mRNA 
stability intact (42). Thus, it would appear that distinct signal-
ing cascades are responsible for the coordinated regulation of 
IL-2 secretion by CD28.
In contrast with the marked defect in proliferation and 
cytokine production, expression of Bcl-XL was less pro-
foundly altered in the CD28-AYAA mutant cells. In studies 
performed by either retroviral gene transfer or transgenic 
mice, a point mutation of Y170 abolished Bcl-XL expression, 
yet left IL-2 intact (14, 23). Similarly, using chimeric con-
structs in human T cells, Parry et al. demonstrated that the 
membrane proximal domain of CD28 was required for Bcl-
XL induction, although both proximal and distal regions were 
necessary for normal IL-2 production (24). The relative pres-
ervation of Bcl-XL expression in the CD28-AYAA knockin 
mutant demonstrates that the mutation has not globally im-
paired CD28 function and is consistent with a requirement 
for the proximal tyrosine based motif as the major pathway 
by which CD28 regulated Bcl-XL expression.
In contrast with reconstitution by retroviral gene transfer 
or transgenic constructs under the control of a heterologous 
promoter, the knockin mouse we have generated allows for 
determination of the eff  ect of the mutation in vivo, with less 
likelihood that that aberrant expression patterns infl  uence the 
result. Given previous data suggesting that this motif was 
critical in the generation of a Th2 response, we examined 
their response in a model of allergic airway infl  ammation. 
This model is CD28-dependent and leads to a Th2-type in-
fl  ammatory response with recruitment of eosinophils to the 
lung and the generation of OVA-specifi  c IgG1 and IgE (26, 
27, 43). Despite the proliferative and cytokine defects ob-
served in vitro, the infl   ammatory response of the mutant 
mice was indistinguishable from wild type as assessed by his-
tology and analysis of the cellular composition of the BAL 
fl  uid. The ability to recruit infl  ammatory cells to the lung 
  after the inhaled antigen challenge suggests that the initial 
priming and clonal expansion of antigen-specifi  c T cells re-
mained intact in the mutant mice. Nonetheless, it remains 
possible that Th2 development was impaired despite the 
presence of eosinophils in the airways (44, 45).
Although the cellular immune response appeared grossly 
intact, the humoral response was signifi  cantly impaired in 
homozygous and heterozygous CD28-AYAA mutant mice. 
There was a drastic reduction in OVA-specifi  c IgG1 in both 
homozygous and heterozygous mutant mice. This was ac-
companied by a failure of the mutant mice to form germinal 
centers in the spleen. Thus, these aspects of CD28 function 
are absolutely dependent on an intact PYAP motif. A re-
quirement for B7:CD28 in humoral responses was fi  rst noted 
in the characterization of mice expressing a soluble CTLA4Ig 
transgene as well as in the characterization of CD28-defi  cient 
mice (46, 47). This may be secondary to the loss of specifi  c 
cognate interactions between T and B cells, as well as defec-
tive cytokine and/or chemokine production by the mutant T 
cells. Although a relative defi  ciency in IL-4 secretion might 
account for the lack of Th2 Ig isotypes, it is unlikely to lead 
to a complete failure to develop germinal centers. However, 
there is an intimate relationship between B7:CD28 and 
CD40:CD40L interactions (48, 49). A failure to up-regulate 
CD40L on the mutant T cells could account for the decreased 
antibody and GC formation, particularly in combination 
with a relative defi  ciency in IL-4 (50). Recent data suggests 
that CD28 regulates the expression of OX40 on T cells and 
that the combined action of CD28 and OX40 is important in 
the expression of CXCR5 on T cells (51, 52). This in turn 
may regulate the migration of T cells into the B cell follicle 
to support the GC reaction. Some investigators have pro-
posed that the T cells supporting the GC reaction may in fact 
be a novel class of T helper cells (53). The requirement for 
costimulation in the development and function of these cells 
is only beginning to be examined.
In summary, our data demonstrates that the C-terminal 
proline motif is critical for normal regulation of proliferation 
and IL-2 production by CD28 in resting naive primary T cells. 
We also have shown that there is an important gene dosage ef-
fect in the mutant phenotype as a twofold change in the ex-
pression level of the mutant protein was suffi   cient to essentially 
normalize cell proliferation, but not IL-2 production. Further-
more, in vivo, this motif discriminates between specifi  c ele-
ments of CD28 that regulate cellular and humoral aspects of 
the immune response in vivo, as it is essential for antibody 
production and GC formation, but not cell-mediated infl  am-
mation. This aspect, in particular, suggests that selective ma-
nipulation of this portion of the CD28 signal transduction 
pathway might be of potential therapeutic value by inhibiting 
humoral responses while preserving cellular immunity.
MATERIALS AND METHODS
Generation of CD28-AYAA knockin construct. A 14-Kb EcoRI frag-
ment containing exon IV of CD28 was cloned from a mouse genomic BAC 
library (Incyte Genomics). This was digested with BamH1 and a LoxP site–
fl  anked Neomycin resistance cassette was inserted into the 5′ BamHI site. The 
1.7-Kb short arm was generated by PCR spanning from the BamHI site to the 
EcoRI site upstream and cloned 5′ to the Neomycin cassette. The resultant JEM VOL. 203, September 4, 2006  2131 
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construct contained two new EcoRI sites fl  anking the Neomycin cassette as 
indicated in Fig. 1. Oligonucleotide-directed site-specifi  c mutagenesis was 
performed to generate specifi  c base pair changes (CCC to GCC and CCT 
to GCT) resulting in a fi  nal sequence that substituted alanine for proline at 
positions 187 and 190. The sequence of the entire exon was verifi  ed by di-
rect sequence analysis. The construct was transfected into 129/Sv embryonic 
stem cells (line RW4, provided by the Siteman Cancer Center, Washington 
University, St. Louis) and neomycin resistant clones were screened for ho-
mologous recombination by Southern blotting of BglII- and EcoRI-digested 
DNA using 5′ and 3′ external probes, respectively (Fig. 1 C). The mutation 
was confi  rmed by direct sequencing of exon IV after PCR amplifi  cation, as 
well as by restriction digestion with HaeIII, as the mutation results in the 
generation of a new HaeIII site (unpublished data). Germline transmission 
was verifi  ed by Southern blotting using both 5′ and 3′ external probes. 
In addition, the presence of the mutation was confi  rmed by both restriction 
digest and direct sequence analysis.
Mice. C57BL/6 mice were purchased from The Jackson Laboratory. CD28-
defi  cient mice on the C57BL/6 background were originally obtained from 
C. Thompson (University of Pennsylvania, Philadelphia, PA). All mice were 
bred and housed under specifi  c pathogen-free conditions at Washington 
University School of Medicine. All animal experimentation has been ap-
proved by Institutional Animal Use and Care Committee at Washington 
University School of Medicine.
Antibodies. Anti-CD3 (145-2c11 hamster IgG) and all fl  uorescently con-
jugated antibodies were purchased from BD Biosciences or eBioscience. For 
staining, fl  uorescently conjugated anti-CD28 (clone 37.5.1) was used. For 
stimulation, anti-CD28 clone PV-1 (Southern Biotechnology Associates, 
Inc.) was used. Anti-Bcl-XL clone 7B2.5 ascites (mouse IgG3) was provided 
by L. Boise (University of Miami, Miami, FL).
RT-PCR. Total RNA was isolated from wild-type or mutant thymocytes 
using TRIzol reagent (Invitrogen). RT-PCR was performed using primers 
specifi  c for exons I and IV of CD28. The product was purifi  ed, digested 
with HaeIII, and electrophoresed on a 15% polyacrylamide gel. The bands 
were visualized after staining with ethidium bromide.
[3H] incorporation assays. Splenocytes were isolated by density gradient 
centrifugation, plated at 105 cells per well of a 96-well plate, and stimulated 
as indicated for each experiment. After 48 h of stimulation, the plates were 
pulsed with tritiated thymidine (1 μCi/well) overnight and harvested the 
following morning. For the mixed lymphocyte response, 5 × 105 spleno-
cytes of each genotype were cocultured with an equal number of BALB/c 
splenocytes that had been γ-irradiated (2,000 rad). After 96 h of stimulation, 
the cultures were pulsed with tritiated thymidine and harvested the follow-
ing morning. Incorporated thymidine was determined by liquid scintillation 
counting. All conditions were plated in quadruplicate and the mean ± the 
standard deviation presented. All experiments have been replicated a mini-
mum of three times and representative data are presented.
CFSE assays. Splenocytes were isolated and incubated at a concentration of 
5.0 × 106 cells/ml with 5 mM CFSE in 1x PBS + 5% FCS for 5 min at 
room temperature. After washing three times with 1x PBS, the cells were 
resuspended in media at 2.0 × 106/ml and stimulated with anti-CD3, anti-
CD28, and CTLA-4 Ig as described. Aliquots of cells were stained with PE-
conjugated anti-CD4 mAb and the intensity of CFSE fl  uorescence of the 
CD4+ cells determined by two-color fl  ow cytometry. Unstimulated cells 
were assayed simultaneously to determine the fl  uorescence intensity of undi-
vided cells. All analysis was done using a FACSCalibur fl  ow cytometer with 
CELLquest Software (Becton Dickinson Corporation).
Cytokines. Splenocytes were isolated and stimulated as described for the 
proliferation assays. After 48 h, culture supernatants were collected and 
assayed for IL-2 using the Quantikine Murine IL-2 ELISA kit as per the 
manufacturer’s protocol (R&D Systems). Additional cytokines were assayed 
using the Bioplex murine Th1/Th2 panel as per the manufacturer’s direc-
tions (BioRad Laboratories).
Flow cytometry. CD28 expression of thymocytes or splenocytes was de-
termined by staining with anti-CD4–FITC and anti-CD28–PE or isotype 
controls and analyzed on a FACSCalibur fl  ow cytometer using CELLquest 
software (Becton Dickinson). Similarly, CD69 expression was determined 
on resting or activated CD4+ T cells by two-color fl  ow cytometric analysis 
using anti-CD4–FITC and PE-conjugated anti-CD69. Bcl-XL expression 
was determined by intracellular staining as previously described (14).
Induction of allergic airway infl  ammation. Mice were immunized i.p. 
on days 0 and 7 with 8 μg OVA absorbed to 2 mg alum (Sigma-Aldrich) 
as previously described (25, 54). On day 14, the mice were intranasally 
  challenged with 2% OVA and specimens collected on the third day after 
  challenge. Bronchoalveolar lavage (BAL) was performed by intratracheal 
  installation of 1% BSA in PBS. Cell diff  erentials were performed on cytospin 
preparations stained with a modifi  ed Wright-Geimsa stain. For histology, 
the lungs were infl  ated with neutral buff  ered formalin to 25 cm of water 
pressure and fi  xed overnight. Samples were progressively dehydrated in eth-
anol and processed for sectioning and H&E staining. Serum was collected at 
the time the mice were killed and antigen-specific immunoglobulin titers 
were determined by specifi  c ELISA as previously described (28). Spleens 
were also harvested and frozen in OCT compound on dry ice. Frozen 
  sections were prepared, fi  xed in acetone, and stained with PNA-biotin and 
rat anti–mouse IgD followed by detection with AP-streptavidin and goat 
anti–rat IgG(H+L)-HRP to detect GCs. Multiple sections were examined 
and the number of GCs/10X fi  eld were determined as well as the total 
  number of GCs per section counted.
Online supplemental material. To determine whether the mutation 
  altered the regulation of CD28 expression after T cell activation, cells were 
stimulated and CD28 expression was determined by fl  ow cytometry (Fig. S1). 
Similarly, CD69 expression was assessed in wild-type and mutant T cells af-
ter activation (Fig. S2). Protein tyrosine phosphorylation and ERK phos-
phorylation was assessed in wild-type and mutant T cells by Western blotting 
(Fig. S3). Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20052230/DC1.
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